The main targeted treatments approved for lung cancer with ROS1 rearrangement include drugs such as Crizotinib, a tyrosine kinase inhibitor initially approved for ALK-positive patients, which has shown significant efficacy in ROS1-positive patients as well [187,204]. Here, ALK is linked to lung cancer.